The North America opioid induced constipation drug market was valued at $2125 million in the year 2016. The market is expected to grow at a CAGR of 5.65% over the forecast period of 2017-2025. The North American is expected to dominate the global OIC drugs market in the near future. The countries analyzed for this region include the United States and Canada. The region of North America has the highest number of patients, (over 50%) suffering from constipation.

NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUG MARKET FORECAST 2017-2025

North America Opioid Induced Constipation Drug Market by Drug Type (Methyl Naltrexone Bromide, Lubiprostone, Naloxegol, Naldemedine, Alvimopan, Dolcanatide, Elobixibat ) by Prescription Type (Prescribed Drugs, Over the Counter Drugs) & by Geography

Request free sample

Report Summary

To learn more about this report, request a free sample copy

The countries analyzed for this region include the United States and Canada. The region of North America has the highest number of patients, (over 50%) suffering from constipation. This factor is majorly propelling the OIC drug market growth. Also, the increase in healthcare spending, technological advancement in cardiology and growing lifestyle oriented diseases are aiding in the expansion of the market.

Some of the major players in the Opioid Induced Constipation Drug market include Pfizer, Ironwood Pharmaceutical Inc, Nektar Therapeutics, Valeant Pharmaceuticals International, Cosmo Pharmaceuticals Sa, C.B. Fleet Company Inc, Allergan Plc, etc.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
RESEARCH METHODOLOGY
- SOURCES OF DATA
  - SECONDARY DATA
  - PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM UP APPROACH
- DATA TRIANGULATION
EXECUTIVE SUMMARY
- MARKET SUMMARY
MARKET OVERVIEW
- MARKET DEFINITION
- KEY MARKET INSIGHTS
- ATTRACTIVE INVESTMENT SCENARIO
- POSITIONING OF KEY OIC DRUGS MANUFACTURERS IN THE MARKET
- MARKET DRIVERS
  - RISING USE OF OPIOID
  - INCREASING GERIATRIC POPULATION
  - INCREASING OPIOIDS PRESCRIPTION IN NORTH AMERICA
  - EASY AVAILABILITY OF IMPROVED AND EFFECTIVE OIC DRUGS
- RESTRAINTS
  - RESEARCH ON PAIN AND NEXT GENERATION ANALGESICS
  - SIDE EFFECTS OF OIC DRUGS
  - UNAWARENESS AND IGNORANCE AMONG PATIENTS
- OPPORTUNITY
  - INCREASING USE OF OPIOIDS
- CHALLENGES
  - LARGE NUMBER OF CONSIDERATIONS WHILE USING OPIOIDS

NORTH AMERICA OIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
- OVERVIEW
  - METHYL NALTREXONE BROMIDE
  - LUBIPROSTONE
  - NALOXEGOL
- PIPELINE DRUG ANALYSIS: PHASE 3: NALDEMEDINE (YEAR OF LAUNCH TO 2022 $ MILLION)
- PIPELINE DRUG ANALYSIS: PHASE 2: ALVIMOPAN, DOLCANATIDE (QUALITATIVE INFORMATION)
- PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH TO 2022 $ MILLION)
NORTH AMERICA OIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
- PRESCRIBED DRUGS
  - BRANDED
  - GENERIC
- OVER THE COUNTER DRUGS
KEY ANALYTICS
- PORTERS FIVE FORCE MODEL
  - INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
  - BARGAINING POWER OF SUPPLIERS
  - BARGAINING POWER OF BUYERS
  - THREAT OF SUBSTITUTE PRODUCTS
  - THREAT OF NEW ENTRANTS
- VENDOR LANDSCAPE
- OPPORTUNITY MATRIX
NORTH AMERICA OIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
- US
- CANADA
COMPANY PROFILE
- IRONWOOD PHARMACEUTICALS INC
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- DAIICHI SANKYO CO LTD
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- PFIZER
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- PROGENICS PHARMACEUTICALS INC
  - OVERVIEW
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- SHIONOGI & CO., LTD.
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- ALLERGAN PLC
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- NEKTAR THERAPEUTICS
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- PURDUE PHARMA L.P.
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- L.A. PHARMA AG
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- MUNDIPHARMA INTERNATIONAL LIMITED
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- ONO PHARMACEUTICAL CO., LTD.
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- THERAVANCE BIOPHARMA INC
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- VALEANT PHARMACEUTICALS INTERNATIONAL
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- COSMO PHARMACEUTICALS SA
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- DAEWOONG PHARMACEUTICAL CO., LTD.
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- B. FLEET COMPANY, INC.
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS
- SUCAMPO PHARMACEUTICALS
  - OVERVIEW
  - PRODUCT PORTFOLIO
  - STRATEGIC MOVES
  - SCOT ANALYSIS

LIST OF TABLES

TABLE 1 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUG MARKET BY COUNTRIES 2017-2025 ($ MILLION)

TABLE 2 PHARMACOLOGICAL APPROACHES TO TREAT OPIOID INDUCED CONSTIPATION

TABLE 3 LAXATIVES USED FOR OPIOID INDUCED CONSTIPATION

TABLE 4 SIDE EFFECTS OF USING LAXATIVES

TABLE 5 PATIENTS UNFIT FOR INTAKE OF OPIOIDS

TABLE 6 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUG MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)

TABLE 7 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)

TABLE 8 PRODUCT PROFILE (LUBIPROSTONE)

TABLE 9 PRODUCT PROFILE (NALOXEGOL)

TABLE 10 PIPELINE PRODUCT PROFILE (NALDEMEDINE)

TABLE 11 PIPELINE PRODUCT PROFILE (ALVIMOPAN, DOLCANATIDE)

TABLE 12 PIPELINE PRODUCT PROFILE (ELOBIXIBAT)

TABLE 13 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

TABLE 14 PRODUCT PROFILE (LUBIPROSTONE)

TABLE 15 NORTH AMERICA PRESCRIBED OIC DRUGS MARKET 2017-2025($ MILLION)

TABLE 16 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)

TABLE 17 PRODUCT PROFILE (METAMUCIL)

TABLE 18 PRODUCT PROFILE (BISACODYL)

TABLE 19 NORTH AMERICA OIC DRUGS MARKET BY COUNTRY, 2017-2025($ MILLION)

LIST OF FIGURESFIGURE 1 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET 2017-2025 ($ MILLION)

FIGURE 2 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUG MARKET BY DRUG TYPE 2016 AND 2025 (%)

FIGURE 3 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)

FIGURE 4 INCREASING NUMBER OF OPIOID PRESCRIPTION ($ MILLION)

FIGURE 5 REASONS FOR THE GROWTH OF OPIOID MARKET.

FIGURE 6 THERAPEUTIC OPIOID USE IN US (G/100,000 POPULATION)

FIGURE 7 COMMON SIDE EFFECTS OF MOVANTIK

FIGURE 8 MAJOR USAGE OF OPIOIDS

FIGURE 9 CONSIDERATIONS TAKEN WHILE THE OPIOID USAGE

FIGURE 10 NORTH AMERICA METHYL NALTREXONE BROMIDE OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 11 NORTH AMERICA LUBIPROSTONE OIC DRUG MARKET 2017-2025 ($MILLION)

FIGURE 12 NORTH AMERICA NALOXEGOL OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 13 NORTH AMERICA PRESCRIBED OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 14 NORTH AMERICA PRESCRIBED BRANDED OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 15 NORTH AMERICA PRESCRIBED GENERIC OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 16 NORTH AMERICA OVER THE COUNTER OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 17 NORTH AMERICA OPIOID INDUCED CONSTIPATION DRUGS MARKET 2017-2025 ($ MILLION)

FIGURE 18 US OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 19 CANADA OIC DRUG MARKET 2017-2025 ($ MILLION)

FIGURE 20 NUMBER OF PRESCRIPTIONS DISPENSED FOR OPIOIDS

Segmentation

NORTH AMERICA OIC DRUGS MARKET BY COUNTRIES 2017-2025 ($ MILLION)
- US
- CANADA
NORTH AMERICA OIC DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)
- OVERVIEW
  - METHYL NALTREXONE BROMIDE
  - LUBIPROSTONE
  - NALOXEGOL
- PIPELINE DRUG ANALYSIS: PHASE 3: NALDEMEDINE (YEAR OF LAUNCH TO 2022 $ MILLION)
- PIPELINE DRUG ANALYSIS: PHASE 2: ALVIMOPAN, DOLCANATIDE (QUALITATIVE INFORMATION)
- PIPELINE DRUG ANALYSIS: PHASE 3: ELOBIXIBAT (YEAR OF LAUNCH TO 2022 $ MILLION)
NORTH AMERICA OIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
- PRESCRIBED DRUGS
  - BRANDED
  - GENERIC
- OVER THE COUNTER DRUGS